BMY Debt / Equity | BRISTOL-MYERS SQUIBB COMPANY

BRISTOL-MYERS SQUIBB COMPANY (BMY) Debt / Equity

2026-06-30: Debt/Equity Ratio 1.92.
2026-03-31: Debt/Equity Ratio 2.2.
2025-12-31: Debt/Equity Ratio 2.43.
2025-09-30: Debt/Equity Ratio 2.63.

Complete source-backed debt/equity ratio history.

Available history: 2008-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical Debt/Equity Ratio

Date	Debt/Equity Ratio
2026-06-30	1.92
2026-03-31	2.2
2025-12-31	2.43
2025-09-30	2.63
2025-06-30	2.81
2025-03-31	2.85
2024-12-31	3.03
2024-09-30	2.89
2024-06-30	3.05
2024-03-31	3.18
2023-12-31	1.34
2023-09-30	1.28
2023-06-30	1.16
2023-03-31	1.17
2022-12-31	1.25
2022-09-30	1.19
2022-06-30	1.28
2022-03-31	1.42
2021-12-31	1.23
2021-09-30	1.19
2021-06-30	1.22
2021-03-31	1.22
2020-12-31	1.33
2020-09-30	0.89
2020-06-30	0.94
2020-03-31	0.92
2019-12-31	0.89
2019-09-30	1.38
2019-06-30	1.52
2019-03-31	0.37
2018-12-31	0.49
2018-09-30	0.51
2018-06-30	0.56
2018-03-31	0.55
2017-12-31	0.59
2017-09-30	0.52
2017-06-30	0.52
2017-03-31	0.55
2016-12-31	0.4
2016-09-30	0.42
2016-06-30	0.45
2016-03-31	0.47
2015-12-31	0.47
2015-09-30	0.48
2015-06-30	0.49
2015-03-31	0.48
2014-12-31	0.53
2014-09-30	0.51
2014-06-30	0.5
2014-03-31	0.49
2013-12-31	0.53
2013-09-30	0.45
2013-06-30	0.5
2013-03-31	0.53
2012-12-31	0.53
2012-09-30	0.52
2012-06-30	0.34
2012-03-31	0.33
2011-12-31	0.34
2011-09-30	0.34
2011-06-30	0.34
2011-03-31	0.34
2010-12-31	0.35
2010-09-30	0.42
2010-06-30	0.42
2010-03-31	0.41
2009-12-31	0.43
2009-09-30	0.45
2009-06-30	0.45
2008-12-31	0.55

Annual Debt/Equity Ratio

Date	Debt/Equity Ratio
2025-12-31	2.43
2024-12-31	3.03
2023-12-31	1.34
2022-12-31	1.25
2021-12-31	1.23
2020-12-31	1.33
2019-12-31	0.89
2018-12-31	0.49
2017-12-31	0.59
2016-12-31	0.4
2015-12-31	0.47
2014-12-31	0.53
2013-12-31	0.55
2011-12-31	0.34
2010-12-31	0.35
2009-12-31	0.43
2008-12-31	0.55

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
PFIZER INC (PFE)	United States	$162.042B	31.94
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64